

- Maternal mortality, 51  
 Maternal serum screening, 83e-4  
 Matrilin-1, 2202  
 Matrix-assisted laser desorption/ionization/time-of-flight mass spectrometry (MALFDI-TOF MS), 150e-3, 183e-1, 194e-3  
 Matrix metalloproteinase 3, 2170  
 Matrix metalloproteinase 9, 1106  
 Matrix metalloproteinase 12, 1701  
 Matrix metalloproteinases (MMPs)  
   in cancer cell signaling, 102e-11f  
   in metastasis, 102e-10  
   in photoaging of skin, 387  
   in rheumatoid arthritis, 2143  
   in tumor angiogenesis, 102e-15, 102e-17f  
 Mat telangiectasias, 356f, 357  
 Maturity-onset diabetes of the young (MODY), 431t, 441t, 2400, 2406  
 Maximum-tolerated dose (MTD), 103e-5  
 Mayaro virus, 837, 1306t  
 Mayer-Rokitansky-Kuster-Hauser syndrome, 335, 2357  
 May-Hegglin anomaly, 729  
 Mazindol, 2396  
 Mazzotti reaction, 246e-8  
 MBC (minimal bactericidal concentration), 150e-9  
 MBL gene, 1240t  
 MBP (myelin basic protein), 372e-24t, 444e-4f  
 McArdle's disease (muscle phosphorylase deficiency; type V GSD), 433e-2t, 433e-4, 462e-14  
 McBurney's point, 1987  
 McConnell's sign, 270e-7, 1634  
 McCune-Albright syndrome, **426e-6**  
   clinical features of  
     adrenal tumors, 2321  
     Cushing's syndrome, 2314-2315  
     cutaneous, 359, 360t  
     endocrinologic, 2266, 2344  
     fibrous dysplasia, 426e-6, 2265t  
     precocious puberty, 2362  
     diagnosis of, 426e-6, 426e-6f  
     genetic considerations in, 439, 2252, 2266, 2314-2315, 2344, 2362, 2476f  
     treatment of, 426e-7  
 MCH (mean cell hemoglobin), 393, 393t, 394t, 2755t  
 MCH (melanin-concentrating hormone), 415e-2  
 MCH/MCV (mean cell hemoglobin concentration), 393, 393t  
 MCI (mild cognitive impairment), 75, 76f, 171  
 MCIIR gene mutations, 386, 494  
 McLeod blood group, 81e-4f  
 McLeod phenotype, 138e-2, 375e-1  
 McMurray test, 2222  
 M component  
   in heavy chain diseases, 718  
   of immunoglobulin, 710-712  
   in multiple myeloma, 715  
   in plasma cell disorders, 712  
   in Waldenström's macroglobulinemia, 718  
 MCP-1 (monocyte chemoattractant protein-1), 372e-11t, 465e-4  
 MCP-2 (monocyte chemoattractant protein-2), 372e-11t  
 MCP-3 (monocyte chemoattractant protein-3), 372e-12t  
 MCP-4 (monocyte chemoattractant protein-4), 372e-12t  
 MCPs (monocyte chemoattractant proteins), 1242  
 M-CSF (macrophage colony-stimulating factor), 372e-11t  
 MCT8 gene mutations, 2286  
 MCTD. *See* Mixed connective tissue disease (MCTD)  
 MCV (mean cell volume), 393, 394t  
 MD-2, 145e-5, 145e-6f  
 MDC (CCL22), 372e-12t, 1674, 1674f  
 MDCT (multidetector computed tomography), 440e-1, 1664-1666. *See also* Computed tomography (CT)  
 MDM2 gene mutations, 562  
 MDM3 gene mutations, 2077  
 MDM4 gene mutations, 562  
 MDMA (ecstasy), 168, 301, 469e-3  
 MDRD equation, 291  
*mdr* (multidrug resistance) gene/phenotype, 102e-10, 103e-23  
 MDS (myelodysplastic syndromes). *See* Myelodysplasia  
 Meadowsweet, 404t  
 Mean arterial pressure, in shock, 1729, 1744, 1757  
 Mean cell hemoglobin (MCH), 393, 394t, 2755t  
 Mean cell hemoglobin concentration (MCH/MCV), 393, 394t, 2755t  
 Mean cell volume (MCV), 393, 394t, 2755t  
 Means-Lerman scratch, 290e-2  
 Measles (rubeola), **1295**. *See also* Rubella (German measles)  
   approach to the patient, 1297  
   atypical, 25e-5f, 362  
   clinical features of, 128t, 1296, 1296f, 1297  
   in impaired immunity, 1297  
   Koplik's spots, 25e-1f, 127, 362, 1297  
   rash  
     atypical, 25e-5f  
     characteristics of, 25e-1f, 128t, 362, 362t, 1297  
     stages of, 127, 362, 1297  
   complications of, 900, 1298, 2673  
   diagnosis of, 1297-1298  
   differential diagnosis of, 1297  
   epidemiology of, 1295-1296  
   eradication of, 1299  
   etiology of, 1295  
   global considerations in, 786, 1295  
   immune response to, 1296f, 1297  
   incidence pre- and postvaccine, U.S., 785t  
   pathogenesis of, 1296, 1296f  
   postexposure prophylaxis, 1298  
   prevention of, 1298-1299. *See also* Measles-mumps-rubella vaccine (MMR)  
   prognosis of, 1298  
   transmission of, 1296  
   treatment of, 1299  
   vitamin A deficiency in, 96e-7  
 Measles-mumps-rubella vaccine (MMR)  
   adverse effects of, 231e-4, 1299  
   contraindications for, 789t  
   coverage with, in U.S., 231e-1  
   precautions for, 789t  
   recommended administration of  
     in adults, 29t, 50-51, 230e-3, 787-788f  
     in cancer patient, 485t  
     in children, 230e-3, 230e-3f, 231e-4, 1298-1299  
     in health care personnel, 231e-4  
     in HIV infection, 798  
     in transplant recipient, 929, 929t  
     storage and handling of, 791  
 Measles vaccine, 794, 1298-1299  
 Measles virus, 145e-1, 145e-2t, 1295. *See also* Measles (rubeola)  
 Mebendazole  
   action of, 246e-10  
   adverse effects of, 246e-3t, 246e-10  
   for ascariasis, 1413  
   drug interactions of, 246e-3t  
   for enterobiasis, 1416  
   for hookworm infections, 1415  
   indications for, 246e-3t  
   pharmacology of, 246e-10  
   in pregnancy and lactation, 246e-3t  
   for trichinellosis, 1411t  
   for trichuriasis, 1416  
*meA* gene, 774, 807, 961  
 Mecamylamine, 2660  
*meC* gene, 774  
 Mechanical heart valve. *See* Prosthetic heart valve  
 Mechanical ptosis, 207  
 Mechanical ventilation, **1740**  
   for ARDS, 1738-1739, 1739t  
   in coma, 1776  
 complications of, 1743  
   alveolar collapse, 1738  
   lung injury, 1731, 1738, 1743  
   pneumonia. *See* Ventilator-associated pneumonia (VAP)  
   respiratory acidosis, 322  
   volutrauma, 1731, 1743  
 continuous positive airway pressure. *See* Continuous positive airway pressure (CPAP)  
   for COPD, 1707  
   for hemoptysis, 247  
   indications for, 1740  
   modes of, 1741-1742, 1742t  
   nonconventional strategies for, 1742-1743  
   noninvasive, 1740-1741, 1741t  
   patient management during, 1732-1733, 1739, 1741, 1743  
   physiology of, 1741, 1741f  
   principles of, 1741, 1741f  
   protective strategies in, 1743  
   for pulmonary edema, 1763  
   for respiratory acidosis, 323  
   for sepsis/septic shock, 1755  
   for shock, 1731  
   tracheostomy in, 1744  
   weaning from, 66-67, 1743-1744, 1744f  
 Mechanic's hands, 2195  
 Mechanoreceptors, in lung, 47e-1  
 Mechanotransduction, 217  
 Mechlorethamine (nitrogen mustard)  
   action of, 103e-8  
   adverse effects of, 103e-8, 103e-9t, 103e-25, 474, 607t  
   carcinogenicity of, 477t  
   as terrorism agent, 262e-1t  
 Meckel-Gruber syndrome, 1850t, 1851f  
 Meckel's diverticulum, 277, 279  
 Mecizine, 62, 260, 260t, 261  
 Meclofenamate, 727t  
 Meconium ileus, 1697  
*MECP2* gene mutations, 431, 444e-4, 465e-2, 465e-2t  
 Médecins Sans Frontières, 12  
 Medial epicondylitis, 2249  
 Medial medullary stroke syndrome, 2576f, 2577  
 Median neuropathy, 2683, 2691  
 Mediastinal (thymic) large B-cell lymphoma, 135e-2  
 Mediastinal mass  
   CT in, 1664, 1665f, 1719  
   diagnosis of, 1719  
   differential diagnosis of, 123e-1  
   thymoma. *See* Thymoma  
 Mediastinitis  
   actinomycotic, 1089  
   acute, 1719  
   anaerobic bacterial, 1098  
   chronic, 1719-1720  
   fibrosing, in histoplasmosis, 1333, 1334  
   nocardial, 1085  
   sternal osteomyelitis and, 844  
   in transplant recipient, 926, 927  
 Mediastinoscopy, 1668  
 Mediastinotomy, 1668  
 Mediastinum, 1719, 1720t  
 Medicaid, 15e-2, 82-83, 83t  
 Medical decision-making, 3, 16e-4  
 Medical education, 7, 17e-4  
 Medical errors, 4, 17e-4  
 Medical kit, traveler's, 797  
 Medical practice, 1, 2f  
   accountability in, 6-7  
   clinical skills and, 1-3  
   ethical issues in. *See* Ethical issues  
   evaluation of outcomes, 3  
   expanding frontiers of, 5-7  
   globalization of, 6. *See also* Global health  
   humane aspects of, 5  
   Internet and, 6  
   legal issues in. *See* Legal issues  
   practice guidelines, 3  
   public expectations of, 6-7